0.8681

4.61% -0.042

After Hours: .83 -0.0381 -4.39%

Conduit Pharmaceuticals Inc (CDT)

Overview News Price History Why CDT Down? Discussions Forecast

Conduit Pharmaceuticals Inc stock is traded at $0.8681, with a volume of 1.54M. It is down -4.61% in the last 24 hours and down -20.36% over the past month. Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Previous Close:

$0.9101

Open:

$0.94

24h Volume:

1.54M

Relative Volume:

0.30

Market Cap:

$8.29M

Revenue:

Net Income/Loss:

$-4.21M

P/E Ratio:

-15.84

EPS:

-0.0548

Net Cash Flow:

1W Performance:

+33.55%

1M Performance:

-20.36%

6M Performance:

-92.01%

1Y Performance:

-99.73%

1-Day Range:

$0.8311

$0.94

1-Week Range:

$0.51

$1.40

52-Week Range:

$0.51

$350.00

Conduit Pharmaceuticals Inc Stock (CDT) Company Profile

Name

Conduit Pharmaceuticals Inc

Sector

Healthcare (1159)

Industry

Biotechnology (679)

Phone

(646) 491 9132

Address

4851 TAMIAMI TRAIL NORTH, NAPLES

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CDT's Discussions on Twitter

Compare CDT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CDT Conduit Pharmaceuticals Inc	0.8681	8.29M	0	-4.21M	0	-0.0548
VRTX Vertex Pharmaceuticals Inc	495.83	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	571.06	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	606.39	36.98B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.01	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	242.75	26.15B	3.81B	-644.79M	-669.77M	-6.24

Conduit Pharmaceuticals Inc Stock (CDT) Latest News

Apr 11, 2025

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener

Apr 11, 2025

Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan

Apr 11, 2025

Apr 10, 2025

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times

Apr 10, 2025

Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan

Apr 10, 2025

Apr 07, 2025

Conduit Pharmaceuticals expands partnership with Sarborg - MSN

Apr 07, 2025

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times

Apr 07, 2025

Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan

Apr 07, 2025

Apr 03, 2025

Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World

Apr 03, 2025

Apr 02, 2025

Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia

Apr 02, 2025

Apr 01, 2025

Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com

Apr 01, 2025

Mar 31, 2025

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times

Mar 31, 2025

Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan

Mar 31, 2025

Mar 28, 2025